Climb Bio Shares Soar on Promising Phase 1 Data for Kidney Disease Drug

Shares of Climb Bio, Inc. (NASDAQ: CLYM) surged 17% in Thursday trading after the biotechnology company announced positive results from a Phase 1 trial of its experimental drug, CLYM116, for the treatment of IgA nephropathy, a chronic kidney disease.

Key Trial Results

The randomized, placebo-controlled study evaluated the safety and activity of CLYM116, an anti-APRIL monoclonal antibody, in 46 healthy volunteers. According to the company's release, the drug was generally well-tolerated with no serious adverse events reported.

Key findings from the trial include:

• A single 320 mg subcutaneous dose led to a near-complete suppression of free APRIL (A Proliferation-Inducing Ligand), a key protein involved in the disease.
• The dose also resulted in a 60-75% suppression of IgA/Gd-IgA1, the disease-causing immunoglobulins, through 12 weeks.
• The drug demonstrated a half-life of approximately 29 days, which Climb Bio noted is about three times longer than a competing therapy, sibeprenlimab.

Path to Market

Ad

The promising data, particularly the drug's long half-life, supports the potential for a convenient quarterly (every-12-week) dosing schedule for patients. Climb Bio reported that its modeling confirms this potential regimen.

Climb Bio is currently evaluating CLYM116 in its ongoing Phase 2 NAVIGATE-2 trial in patients with IgA nephropathy. The company anticipates releasing initial data from this study in the first half of 2027 and plans to initiate a pivotal Phase 3 registrational study later that year.

Market Implications

The significant stock price increase reflects investor optimism about CLYM116's potential as a competitive treatment for IgA nephropathy. A less frequent dosing schedule could be a key differentiator in the market. The company also confirmed it has completed the development of a pre-filled syringe for the drug and is developing an autoinjector, which would further enhance patient convenience.